Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 3,4813,500 of 20,252 grants

Active NON-SBIR/STTR RPGS
The Thromboxane-Prostanoid Receptor in Radiation-Induced Pulmonary Fibrosis
NATIONAL CANCER INSTITUTE Vanderbilt University Medical Center United States 2023 – 2028

Project Summary: Radiation induced lung injury is a crucial dose-limiting factor in patients receiving thoracic radiotherapy, affecting a significant proportion of patients even wi...

$6.9M
USD
Completed NON-SBIR/STTR RPGS
dMRI-guided pre-operative planning for supra-total resection of high-grade gliomas
NATIONAL CANCER INSTITUTE University of Pennsylvania United States 2023 – 2023

ABSTRACT High-grade gliomas (HGGs) are the most common primary brain malignancy in adults associated with very poor survival rates despite various treatments. Surgery is the curren...

$877.8K
USD
Active NON-SBIR/STTR RPGS
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2026

Men with biochemical recurrence after prostatectomy receiving salvage radiation (RT) may benefit from added anti-androgen therapy (AAT) by decreasing their likelihood of progressin...

$6.23M
USD
Active NON-SBIR/STTR RPGS
Elucidating the Consequences of Chromosome 3 Arm Aneuploidies in Squamous Cell Carcinoma
NATIONAL CANCER INSTITUTE Columbia University Health Sciences United States 2023 – 2028

PROJECT SUMMARY Aneuploidy, the gain or loss of whole chromosomes or chromosome arms, is a near-universal feature of cancer. However, the role of aneuploidy in tumor pathogenesis r...

$4.02M
USD
Active OTHER RESEARCH-RELATED
The role of IL6-induced LAG3 as a resistance mechanism to PD1 blockade in NSCLC patients
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT: Despite the landmark approval of anti-PD1 therapy for non-small cell lung cancer (NSCLC), the majority of patients still progress. Compensatory activation...

$2.76M
USD
Completed TRAINING, INDIVIDUAL
Hypertrophic adipocytes as biophysical mediators of breast cancer progression
NATIONAL CANCER INSTITUTE Cornell University United States 2023 – 2025

PROJECT SUMMARY Over 40% of adult women in the U.S. are obese and obesity will soon overtake smoking as the leading risk factor for cancer. For breast cancer, obese women demonstra...

$478.5K
USD
Active TRAINING, INDIVIDUAL
Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung Cancer
NATIONAL CANCER INSTITUTE University of Missouri-Columbia United States 2023 – 2027

PROJECT SUMMARY Cancer is set to bypass cardiovascular disease as the number one cause of death in United States and it is a leading cause of death worldwide. Non-Small Cell Lung C...

$346.6K
USD
Active TRAINING, INDIVIDUAL
Targeting Metabolic Vulnerabilities with Synergistic Therapeutic Agents for Treatment of Metastatic Castration-Resistant Prostate Cancer.
NATIONAL CANCER INSTITUTE University of Texas At Austin United States 2023 – 2026

PROJECT SUMMARY Broad Impact: Prostate cancer (PCa) is the most commonly diagnosed cancer in American men and in 2022 alone will result in the death of over 34,000 men. PCa mortali...

$395.4K
USD
Active TRAINING, INDIVIDUAL
Targeting Metabolic Vulnerabilities with Synergistic Therapeutic Agents for Treatment of Metastatic Castration-Resistant Prostate Cancer.
NATIONAL CANCER INSTITUTE University of Texas At Austin United States 2023 – 2026

PROJECT SUMMARY Broad Impact: Prostate cancer (PCa) is the most commonly diagnosed cancer in American men and in 2022 alone will result in the death of over 34,000 men. PCa mortali...

$382.6K
USD
Completed TRAINING, INDIVIDUAL
Hypertrophic adipocytes as biophysical mediators of breast cancer progression
NATIONAL CANCER INSTITUTE Cornell University United States 2023 – 2025

PROJECT SUMMARY Over 40% of adult women in the U.S. are obese and obesity will soon overtake smoking as the leading risk factor for cancer. For breast cancer, obese women demonstra...

$465.7K
USD
Active TRAINING, INDIVIDUAL
Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung Cancer
NATIONAL CANCER INSTITUTE University of Missouri-Columbia United States 2023 – 2027

PROJECT SUMMARY Cancer is set to bypass cardiovascular disease as the number one cause of death in United States and it is a leading cause of death worldwide. Non-Small Cell Lung C...

$333.8K
USD
Active NON-SBIR/STTR RPGS
Elucidating the Consequences of Chromosome 3 Arm Aneuploidies in Squamous Cell Carcinoma
NATIONAL CANCER INSTITUTE Columbia University Health Sciences United States 2023 – 2028

PROJECT SUMMARY Aneuploidy, the gain or loss of whole chromosomes or chromosome arms, is a near-universal feature of cancer. However, the role of aneuploidy in tumor pathogenesis r...

$3.79M
USD
Active OTHER RESEARCH-RELATED
The role of IL6-induced LAG3 as a resistance mechanism to PD1 blockade in NSCLC patients
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT: Despite the landmark approval of anti-PD1 therapy for non-small cell lung cancer (NSCLC), the majority of patients still progress. Compensatory activation...

$2.76M
USD
Completed TRAINING, INDIVIDUAL
Examining Early Life Risk Factors and Patterns of Screening for Early-Onset Colorectal Cancer
NATIONAL CANCER INSTITUTE Yale University United States 2023 – 2025

PROJECT SUMMARY/ABSTRACT In the United States (US), the incidence of early-onset colorectal cancer (EOCRC), defined as colorectal cancer (CRC) diagnosed among individuals

$489.7K
USD
Completed TRAINING, INDIVIDUAL
Examining Early Life Risk Factors and Patterns of Screening for Early-Onset Colorectal Cancer
NATIONAL CANCER INSTITUTE Yale University United States 2023 – 2025

PROJECT SUMMARY/ABSTRACT In the United States (US), the incidence of early-onset colorectal cancer (EOCRC), defined as colorectal cancer (CRC) diagnosed among individuals

$476.9K
USD
Completed NON-SBIR/STTR RPGS
MASTER Scaffolds for Rapid, Single-Step Manufacture and Prototyping of CAR-T cells
NATIONAL CANCER INSTITUTE North Carolina State University Raleigh United States 2023 – 2024

PROJECT SUMMARY Despite the unprecedented clinical success of chimeric antigen receptor (CAR) T cell therapy, its widespread application is limited by lengthy and labor-intensive e...

$1.18M
USD
Active NON-SBIR/STTR RPGS
Integration of Immunology and Microbiology into Molecular Pathological Epidemiology of Colorectal Cancer
NATIONAL CANCER INSTITUTE Brigham and Women'S Hospital United States 2023 – 2028

Summary Colorectal cancer is a heterogenous disease influenced by somatic mutations, microbiota, host immunity, and risk factor exposures, necessitating integrative research approa...

$1.69M
USD
Active NON-SBIR/STTR RPGS
Integration of Immunology and Microbiology into Molecular Pathological Epidemiology of Colorectal Cancer
NATIONAL CANCER INSTITUTE Brigham and Women'S Hospital United States 2023 – 2028

Summary Colorectal cancer is a heterogenous disease influenced by somatic mutations, microbiota, host immunity, and risk factor exposures, necessitating integrative research approa...

$1.69M
USD
Active NON-SBIR/STTR RPGS
In vivo prime editing for precision cancer mouse models
NATIONAL CANCER INSTITUTE University of Massachusetts Med Sch Worc... United States 2023 – 2028

Project Summary/Abstract Cancer genomic studies have identified a large number of mutations, including point mutations, insertions/deletions (indels), and structural variants in co...

$6.26M
USD
Active NON-SBIR/STTR RPGS
In vivo prime editing for precision cancer mouse models
NATIONAL CANCER INSTITUTE University of Massachusetts Med Sch Worc... United States 2023 – 2028

Project Summary/Abstract Cancer genomic studies have identified a large number of mutations, including point mutations, insertions/deletions (indels), and structural variants in co...

$5.94M
USD